Skip to main content
. Author manuscript; available in PMC: 2014 Apr 15.
Published in final edited form as: J Immunol. 2013 Mar 18;190(8):4056–4065. doi: 10.4049/jimmunol.1202640

Figure 2. Anti-IL-4 treatment of CD8-deficient recipients of CD8+ T cells prevents restoration of AHR and inflammation.

Figure 2

(A) Changes in airway resistance (RL) were measured in response to increasing concentrations of methacholine. (B) Cell composition in BAL fluid. Cytokine levels in BAL fluid. The top 2 graphs show IFN-γ (C) and IL-13 (D) levels and the bottom 2 graphs show IL-4 (E) and IL-5 (F) levels. (G) Representative photomicrographs of lung histology (×200). Quantitative analysis of goblet cells was as described in Materials and Methods. (H) IFN-γ and IL-13 expression in recovered lung CD8+ T cells. Data (mean±SEM) were from at least 6–10 mice. **p<0.01 and *p<0.05 compared to sensitized and challenged CD8-deficient recipients of 5×106 IL-2-differentiated CD8+ T cells group. ##p<0.01 compared to sensitized and challenged CD8-deficient recipients of 5×106 IL-2-differentiated CD8+ T cells treated with an isotype control.